Netherlands-based myTomorrows has entered a collaboration with Clínica Universidad de Navarra (CUN) to implement AI clinical trial matching, integrating into CUN’s electronic health record (EHR) and functioning within its controlled clinical setting.
This partnership marks myTomorrows’ inaugural extensive site partnership in Spain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to myTomorrows, the partnership brings forth an AI-driven eligibility support system aimed at improving that process within the current clinical workflows.
The system uses large language models to evaluate both unstructured medical documentation in various languages and structured clinical variables such as staging, diagnosis, prior therapies, and molecular profile.
Patient data is then systematically compared with protocol-defined eligibility criteria and real-time cohort status across CUN’s active trials.
Clinicians can access a structured list of eligible trials directly within a patient’s record during routine reviews. This integration supports consistent screening across tumour boards, pre-consultation checks, and outpatient workflows, minimising manual cross-referencing and reducing the risk of overlooking specific cohorts.
CUN clinicians first assessed AI matching capabilities in a secure, General Data Protection Regulation (GDPR)-compliant web environment using real clinical scenarios.
Following evaluation, the technology was integrated into CUN’s EHR and trial management systems, enabling direct operation within hospital infrastructure.
The partnership also aims to strengthen referral coordination between CUN and external institutions.
Utilising myTomorrows’ technology, a CUN-branded website will offer referring physicians insight into the former’s ongoing trials and the status of cohorts in real-time.
In this secure environment, compliant with GDPR regulations, physicians will have the capability to pre-screen patients using AI against CUN’s portfolio and submit referrals based on the latest eligibility criteria and availability of cohorts.
By facilitating an eligibility review before submission, this model enhances communication clarity, minimises administrative exchanges, and ensures that referrals align with the current requirements of CUN’s trials.
CUN will provide ongoing feedback to refine the model as myTomorrows’ first partner site in Spain.
myTomorrows CEO Michel van Harten said: “This partnership reflects the kind of collaboration we’re looking to scale globally. CUN’s established record in clinical research and technology adoption, combined with its expertise as a reference centre, makes it a trusted partner as we continue building more systematic and scalable solutions for clinical trial operations.
“We look forward to working closely with CUN, drawing on real-world clinical experience to further strengthen these models, and to expanding with partners who share CUN’s commitment to more efficiently connect patients with innovative, developing treatments.”
In August 2024, MyTomorrows partnered with multi-stakeholder pressure group Pancreatic Cancer Europe in a bid to drive access to novel treatments across the continent by way of the company’s clinical trials database.
